GlassScriptPhysician profile
Jesse Ninmol
NPI 1093493322
$2,808.41
in general payments reported to CMS, 2019-2025
12 companies · $2,360 in 2025
The $2,360 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $449 · 2025: $2,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,808.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $707.64 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $490.75 | 2025 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $486.88 | 2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $230.38 | 2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.68 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $146.92 | 2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $133.18 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $129.30 | 2025 | Uzedy |
| Neurocrine Biosciences, INC. | $116.33 | 2025 | |
| Axsome Therapeutics, INC. | $104.38 | 2025 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $60.57 | 2024 | Abilify Asimtufii |
| Lundbeck LLC | $26.40 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Ninmol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.